From GlobeNewswire: 2025-02-13 19:45:51

Theratechnologies announced the resumption of EGRIFTA SVMD distribution in the US after FDA authorization. The company is ready to ship two recently manufactured batches to pharmacies within their network. A Prior Approval Supplement submitted to the FDA is under review, with a target date of April 18, 2025. EGRIFTA SVMD is currently distributed exclusively in the United States. The company focuses on innovative treatments that could redefine healthcare standards. Investors are advised to carefully consider the risks and uncertainties associated with the statements made in the press release.



Read more at GlobeNewswire: Theratechnologies reprend la distribution d’EGRIFTA SV(MD)